Negative news coverage of statins may lead people to stop taking their medication; second patient dies in Zafgen obesity drug trial; Gilead defends pricing
Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids
The small screen makes it a user-friendly medication adherence tool.
For all the scientific tools that have fallen into our hands in the past few years, we are still largely falling short in our efforts to influence our audiences' behaviors.
Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.
A small physician survey shows doctors think their patients have higher adherence rates than the norm.
Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.
A CVS Health/American Council of the Blind collaboration means some visually impaired patients will soon have more engaging prescription labels.
More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.
Researchers studying the distribution of brick-and-mortar pharmacies in Chicago link adherence issues with geographic barriers to care.
A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.
A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.
Researchers at the Brigham and Women's Hospital found that continuity in color and shape have a significant impact on whether patients stick with a prescription regimen.
Patients want to do more with mobile and see doctors less. Two studies outline the types of digital interventions patients are interested in.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.
A study showed that side-effect fears keep asthmatics from sticking to medication regimens.
A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.
A roundup of some exchange-related news circling the web.
Researchers say using additional data points offers greater insight into patient-adherence patterns.
Gilead in an other sofosbuvir IP fight; study says patients not sticking with Amgen's Brilinta; AstraZeneca and Cytokinetics drug fails to hit Phase II target; Otsuka gets a CRL
Eisai uses a lawsuit to prompt the DEA, AHRQ gets a new director, mWellness runs into adherence issues.
Proteus Digital Health's ingestible sensor shows utility as an adherence tool for those on psych meds, a study suggests.
Three studies take on different angles of the patient experience. Spoiler alert: no cost increases are mentioned.
For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.
Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.
Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves